Nanoco Group (LSE:NANO), the developer and manufacturer of cadmium-free quantum dots and other nanomaterials, said trading for the year to 31 July was in line with market expectations in a pre-results update.
Unaudited revenue came in at £11.3m, matching forecasts, though stripping out licence agreement income leaves underlying revenue of just £1.5m.
Underlying unaudited adjusted EBITDA reached £6.1m and cash stood at £9.3m at year end, both slightly ahead of expectations, following a cost-base reorganisation that has cut the monthly gross cash cost to £0.3m-£0.4m from £0.5m a year earlier.
The company said it remains on track to hit all first-year milestones under its three-year joint development agreement with its first Asian chemical customer, with volumes expected to more than double in the 2027 financial year from a small base.
Discussions continue with a second Asian chemical customer following a small programme extension in June, alongside engagement with other potential customers on further development agreements or supply contracts, primarily in sensing applications.
The shareholder consultation process launched on 26 June remains ongoing following receipt of submissions.
Full-year results are due later this calendar year.
News Intelligence what this means for the company
Nanoco reported full-year revenue of £11.3m matching forecasts, but underlying revenue (excluding licence agreement income) was just £1.5m—a stark reminder that most reported revenue flows from a single licensing deal rather than core product traction. Cash of £9.3m and adjusted EBITDA of £6.1m both beat expectations, aided by cost cuts that halved monthly burn to £0.3m–£0.4m, but the company remains heavily dependent on its first Asian chemical customer's ramp and early-stage talks with a second customer.
The headline beat masks a fragile revenue base: £9.7m of the £11.3m total comes from licence income, leaving core product revenue negligible. The company's runway has improved materially—at current burn, £9.3m cash covers 23–31 months—but execution risk on the Asian customer's volume ramp (expected to more than double from a small base in FY2027) and the unresolved shareholder consultation remain critical unknowns.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
